CHOSA Oncology AB publishes results from clinical phase 2 trial of liposomal formulation in breast cancer, using predictive marker for cisplatin
[En bild som visar text, skärmbild, Teckensnitt, nummer Automatiskt genererad beskrivning] CEO Peter Buhl comments: “CHOSA presents these important findings that have crystallized by deep clinical knowledge and years of dedication to developing LiPlaCis and its response prediction test DRP”. We welcome interaction and look forward to discussing this at the ASCO poster session that opens today: Abstract number and title: 3130; Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancerSession: Developmental